Jeff Jonker

Jeff Jonker, CEO of Belharra Therapeutics, discusses the renaissance in small molecule drug discovery. Topics include their accidental entry into biotech, the significance of building relationships in the industry, the appeal of sustainable platform companies, chemo proteomics, small molecule binders and covalent bonds in drug discovery, and covalent and non-covalent binding in small molecule drug discovery.